| Autor: |
Yuji Murakawa, MD, Akihiko Nogami, MD, Morio Shoda, MD, Koichi Inoue, MD, Shigeto Naito, MD, Koichiro Kumagai, MD, Yasushi Miyauchi, MD, Teiichi Yamane, MD, Norishige Morita, MD, Hideo Mitamura, MD, Ken Okumura, MD |
| Jazyk: |
angličtina |
| Rok vydání: |
2015 |
| Předmět: |
|
| Zdroj: |
Journal of Arrhythmia, Vol 31, Iss 1, Pp 29-32 (2015) |
| Druh dokumentu: |
article |
| ISSN: |
1880-4276 |
| DOI: |
10.1016/j.joa.2014.05.003 |
| Popis: |
Background: Catheter ablation has become an established therapy for the treatment of atrial fibrillation (AF). To obtain a perspective on the current status of this therapy in Japan, the Japanese Heart Rhythm Society (JHRS) conducted a nationwide survey, the Japanese Catheter Ablation Registry of Atrial Fibrillation (J-CARAF). In this study, we focused on whether periprocedural use of novel oral anticoagulants (NOACs) was related with excessive thromboembolic or bleeding complications. Methods: Using an online questionnaire, JHRS requested electrophysiology centers in Japan to register the data of patients who underwent AF ablations in September 2011, March 2012, and September 2012. We compared the clinical profiles and ablation data, including the incidence of complications among patients in whom warfarin, a NOAC or neither was used as a periprocedural anticoagulant. Results: A total of 179 centers submitted data relating to 3373 patients (62.2±10.6 years). Paroxysmal atrial fibrillation (PAF) was observed in 64.4% of patients. Warfarin, as a periprocedural oral anticoagulant, was used by 53.6% (1808/3373) of patients. A NOAC was given to 541 subjects (dabigatran: 504 [16.1%], rivaroxaban: 37 [1.1%]). In the remaining 1024 patients (30.4%), no periprocedural oral anticoagulants (OACs) were used. The proportion of PAF in warfarin-treated patients (61.1%) was significantly lower than that in NOAC-treated patients (70.1%, p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text